FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2899655750> ?p ?o ?g. }

• W2899655750 endingPage "175883591880733" @default.
• W2899655750 startingPage "175883591880733" @default.
• W2899655750 abstract "Background: Improving outcomes for patients with human epidermal growth factor 2-positive (HER2+) central nervous system (CNS) metastases remains an unmet clinical need. This trial evaluated a novel combination of everolimus, lapatinib and capecitabine for this disease. Methods: Patients with trastuzumab-pretreated, HER2+ breast cancer brain metastasis without prior therapy with a mammalian target of rapamycin (mTOR) inhibitor were eligible. Patients received lapatinib and everolimus daily (continuously) and capecitabine twice daily (d1–14) in 21-d cycles. The primary endpoint was the 12-week CNS objective response rate (ORR). Secondary endpoints included safety, progression-free survival (PFS), overall survival (OS), best CNS ORR and extra-CNS ORR. Results: A total of 19 participants were enrolled and treated with ⩾1 dose of the study drug. The median age was 58.5 years, the median number of therapies for metastatic breast cancer was 2.5 (0–11). Pretrial, 74% of participants had received prior lapatinib, capecitabine or both. A total of 63% had received previous CNS radiation or surgical resection and CNS radiation. The maximum tolerated doses were lapatinib at 1000 mg, everolimus at 10 mg, and capecitabine at 1000 mg/m 2 . Phase II proceeded with capecitabine at 750 mg/m 2 due to better tolerability. The most common grade 3/4 adverse events were mucositis (16%), diarrhea, fatigue, and hypokalemia (11% each). Of 11 participants evaluable for 12-week CNS ORR, 3 (27%) had partial response and 7 (64%) had stable disease. The best CNS ORR in eligible participants was 28% (5/18). The median PFS and OS were 6.2 and 24.2 months, respectively. Conclusions: This novel triplet combination of lapatinib, everolimus, and capecitabine is well tolerated and yielded a 27% response rate in the CNS at 12 weeks in heavily pretreated participants. Larger studies are warranted to further evaluate this regimen. Trial registration: ClinicalTrials.gov: NCT01783756. Registered 05 February 2013, https://clinicaltrials.gov/ct2/show/NCT01783756" @default.
• W2899655750 created "2018-11-16" @default.
• W2899655750 creator A5001424781 @default.
• W2899655750 creator A5006833815 @default.
• W2899655750 creator A5010108379 @default.
• W2899655750 creator A5013532323 @default.
• W2899655750 creator A5015491002 @default.
• W2899655750 creator A5016063259 @default.
• W2899655750 creator A5032190286 @default.
• W2899655750 creator A5037607041 @default.
• W2899655750 creator A5039728399 @default.
• W2899655750 creator A5039832836 @default.
• W2899655750 creator A5042370448 @default.
• W2899655750 creator A5045119268 @default.
• W2899655750 creator A5059305054 @default.
• W2899655750 creator A5068059897 @default.
• W2899655750 creator A5073443262 @default.
• W2899655750 creator A5078184758 @default.
• W2899655750 creator A5078290835 @default.
• W2899655750 creator A5083458902 @default.
• W2899655750 date "2018-01-01" @default.
• W2899655750 modified "2023-10-13" @default.
• W2899655750 title "Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09)" @default.
• W2899655750 cites W1991330252 @default.
• W2899655750 cites W1994363960 @default.
• W2899655750 cites W2013669698 @default.
• W2899655750 cites W2017562064 @default.
• W2899655750 cites W2019607817 @default.
• W2899655750 cites W2026569756 @default.
• W2899655750 cites W2040584772 @default.
• W2899655750 cites W2040935952 @default.
• W2899655750 cites W2044702943 @default.
• W2899655750 cites W2056111473 @default.
• W2899655750 cites W2073865770 @default.
• W2899655750 cites W2076668534 @default.
• W2899655750 cites W2077252057 @default.
• W2899655750 cites W2085739690 @default.
• W2899655750 cites W2090403447 @default.
• W2899655750 cites W2098775844 @default.
• W2899655750 cites W2103808574 @default.
• W2899655750 cites W2115425452 @default.
• W2899655750 cites W2118600577 @default.
• W2899655750 cites W2120330392 @default.
• W2899655750 cites W2127714076 @default.
• W2899655750 cites W2141712412 @default.
• W2899655750 cites W2142364508 @default.
• W2899655750 cites W2143348087 @default.
• W2899655750 cites W2146384083 @default.
• W2899655750 cites W2146778486 @default.
• W2899655750 cites W2149773268 @default.
• W2899655750 cites W2149908785 @default.
• W2899655750 cites W2167188058 @default.
• W2899655750 cites W2167660860 @default.
• W2899655750 cites W2168814163 @default.
• W2899655750 cites W2288763477 @default.
• W2899655750 cites W2318605753 @default.
• W2899655750 cites W2410979882 @default.
• W2899655750 cites W2716808802 @default.
• W2899655750 doi "https://doi.org/10.1177/1758835918807339" @default.
• W2899655750 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6236634" @default.
• W2899655750 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30542377" @default.
• W2899655750 hasPublicationYear "2018" @default.
• W2899655750 type Work @default.
• W2899655750 sameAs 2899655750 @default.
• W2899655750 citedByCount "25" @default.
• W2899655750 countsByYear W28996557502019 @default.
• W2899655750 countsByYear W28996557502020 @default.
• W2899655750 countsByYear W28996557502021 @default.
• W2899655750 countsByYear W28996557502022 @default.
• W2899655750 countsByYear W28996557502023 @default.
• W2899655750 crossrefType "journal-article" @default.
• W2899655750 hasAuthorship W2899655750A5001424781 @default.
• W2899655750 hasAuthorship W2899655750A5006833815 @default.
• W2899655750 hasAuthorship W2899655750A5010108379 @default.
• W2899655750 hasAuthorship W2899655750A5013532323 @default.
• W2899655750 hasAuthorship W2899655750A5015491002 @default.
• W2899655750 hasAuthorship W2899655750A5016063259 @default.
• W2899655750 hasAuthorship W2899655750A5032190286 @default.
• W2899655750 hasAuthorship W2899655750A5037607041 @default.
• W2899655750 hasAuthorship W2899655750A5039728399 @default.
• W2899655750 hasAuthorship W2899655750A5039832836 @default.
• W2899655750 hasAuthorship W2899655750A5042370448 @default.
• W2899655750 hasAuthorship W2899655750A5045119268 @default.
• W2899655750 hasAuthorship W2899655750A5059305054 @default.
• W2899655750 hasAuthorship W2899655750A5068059897 @default.
• W2899655750 hasAuthorship W2899655750A5073443262 @default.
• W2899655750 hasAuthorship W2899655750A5078184758 @default.
• W2899655750 hasAuthorship W2899655750A5078290835 @default.
• W2899655750 hasAuthorship W2899655750A5083458902 @default.
• W2899655750 hasBestOaLocation W28996557501 @default.
• W2899655750 hasConcept C121608353 @default.
• W2899655750 hasConcept C126322002 @default.
• W2899655750 hasConcept C143998085 @default.
• W2899655750 hasConcept C197934379 @default.
• W2899655750 hasConcept C203092338 @default.
• W2899655750 hasConcept C2775930923 @default.
• W2899655750 hasConcept C2777329042 @default.
• W2899655750 hasConcept C2777909004 @default.

• next